Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FRTX - Fresh Tracks Therapeutics Inc


Previous close
0.805
0   0%

Share volume: 73,138
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.80
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-5.88%
1 Month
-20.00%
3 Months
-13.04%
6 Months
-11.80%
1 Year
-0.12%
2 Year
-0.12%
Key data
Stock price
$0.80
P/E Ratio 
-0.84
DAY RANGE
N/A - N/A
EPS 
-$1.06
52 WEEK RANGE
$0.55 - $1.03
52 WEEK CHANGE
-$0.00
MARKET CAP 
4.779 M
YIELD 
N/A
SHARES OUTSTANDING 
5.973 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$6,110
AVERAGE 30 VOLUME 
$2,635
Company detail
CEO: Robert Brown
Region: US
Website: https://brickellbio.com/
Employees: 9
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

brickell biotech, inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. our management team and board of directors has extensive experience in product development, having served in leadership roles at several pharmaceutical and successful start-up companies. our strategy is to leverage this experience to in-license, acquire, develop and commercialize products that we believe can be successful in the global dermatology marketplace. our portfolio of five product candidates, all new molecular entities with relevant mechanism of actions in skin diseases, targets significant market opportunities.

Recent news